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Abstract
Salvianolic acids are the most abundant water-soluble compounds extracted from Radix Salvia miltiorrhiza
(Danshen). In China, Danshen has been wildly used to treat cardiovascular diseases for hundreds of years.
Salvianolic acids, especially salvianolic acid A (Sal A) and salvianolic acid B (Sal B), have been found to have potent
anti-oxidative capabilities due to their polyphenolic structure. Recently, intracellular signaling pathways regulated
by salvianolic acids in vascular endothelial cells, aortic smooth muscle cells, as well as cardiomyocytes, have been
investigated both in vitro and in vivo upon various cardiovascular insults. It is discovered that the cardiovascular
protection of salvianolic acids is not only because salvianolic acids act as reactive oxygen species scavengers, but
also due to the reduction of leukocyte-endothelial adherence, inhibition of inflammation and metalloproteinases
expression from aortic smooth muscle cells, and indirect regulation of immune function. Competitive binding of
salvianolic acids to target proteins to interrupt protein-protein interactions has also been found to be a mechanism
of cardiovascular protection by salvianolic acids. In this article, we review a variety of studies focusing on the above
mentioned mechanisms. Besides, the target proteins of salvianolic acids are also described. These results of recent
advances have shed new light to the development of novel therapeutic strategies for salvianolic acids to treat
cardiovascular diseases.
Introduction
Salvianolic acid is one of the bioactive compounds of
S. miltiorrhiza BGE extracted from the root of S. miltior-
rhiza, commonly named “Danshen” in China. According
to traditional Chinese medicine, Danshen can be used to
promote blood flow and to resolve blood stasis. There-
fore, it is wildly prescribed to patients with angina pec-
toris, hyperlipidemia, and acute ischemic stroke [1-3].
Using chromatographic fingerprinting method and mass
spectrometry, there are more than eighteen components
in Radix S. miltiorrhiza. They can be classified as water-
soluble (hydrophilic) phenolic compounds and nonpolar
(lipid-soluble) diterpenoidal compounds [4,5]. Salvianolic
acids are the main water-soluble compound in S. miltior-
rhiza. Among salvianolic acids, Sal A and Sal B are the
most abundant components. The structures of salvianolic
acids are shown in figure 1.
The bioavailability, pharmacodynamics as well as phar-
macokinetics of salvianolic acids have been investigated.
Due to first-order absorption, Sal B reaches the maxi-
mum plasma concentration within 0.5-1 hour and could
be detected up to 180 minutes after oral administration
[6,7], and which undergoes hepatobiliary excretion [8]. In
conscious and freely moving rat, Wu et al. demonstrates
that Sal B shows the linearity over a plasma concentra-
tion range of 0.5-200 μg/ml and 83.78 ± 10.5% of plasma
protein binding rate. By intravenous injection, 100 mg/kg
Sal B reaches the maximal plasma concentration (Cmax)
around 910 μg/ml, and the half life (t1/2) of Sal B is
around 105 minutes [7]. For oral administration, the
Cmax of 500 mg/kg Sal B is 1.5 μg/ml while 100 mg/kg
Sal A is only 308 ng/ml; the t1/2 is around 248 minutes
for Sal B and 3.29 hours for Sal A [7,9]. The oral bioavail-
ability of Sal B in a conscious rat is calculated to be 2.3%
[7], which is higher than rats under general anesthesia
reported by Zhang et al [10].
Although the therapeutic potential of salvianolic acids
on hepatic protection [11,12], neural protection [13,14],
and cancer treatment [15-17] have been proposed in
recent years, the greatest clinical impact of salvianolic
acids is cardiovascular protection. In the past few years,
mechanism(s) of how salvianolic acids regulate endothelial
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cells, vascular smooth muscle cells and cardiomyocytes
have been investigated. In this article, we summarize
results of these studies on the cardiovascular protective
effect of salvianolic acids and elucidate the multiple
mechanisms of these small compounds in terms of reac-
tive oxygen species (ROS) scavenging ability, leukocyte-
endothelial adhesion regulation, inflammation inhibition
and immune-modulation. In addition, intracellular signal-
ing pathway regulated by salvianolic acids as well as puta-
tive proteins targeted by salvianolic acids are described in
this article.
Cardiovascular Peotection of Salvianolic Acids
A.
Salvianolic Acids Serve As Potent Ros Scavengers During
Cardiovascular Injury
Due to their polyphenolic structure, salvianolic acids are
thought to be free radical scavengers. Indeed, both Sal B
and Sal A show their high radical scavenging capacity
measured by neutralizing free radicals assays such as
DPPH radical scavenging test or ABTS assay [18-20].
Liu et al reported that seven phenolic compounds iso-
lated from S. miltiorrhiza inhibited lipid peroxidation of
rat liver microsomes induced by iron/cysteine and vita-
min C/NADPH and the hemolysis of rat erythrocytes
induced by H2O2 in vitro [21]. It was found that Sal A
was the most potent antioxidant among the salvianolic
acids. However, Sal B was thought to have much more
commercial value for the food and medicine purposes
due to the containment of the highest amounts in S.
miltiorrhiza [4,18,21]. Sal B exhibited higher scavenging
activities than vitamin C against HO·, O2·-, DPPH
radicals, and ABTS radicals. However, their iron chelat-
ing and H2O2 scavenging activities were lower than vita-
min C [20].
Salvianolic acids were not only demonstrated to have
antioxidant activity in vitro, but also been proven to act
as cardiovascular protectors in vivo. Using ischemia-
reperfusion injury model of an isolated rat heart, it was
demonstrated that Sal A lowered the ventricular fibrilla-
tion rate, decreased cellular LDH leaking and reduced
lipid peroxidation in damaged cardiac tissue [22]. Wu
and Hong et al reported that feeding with 5% water-
soluble extract of S miltiorrhiza which contained Sal B
significantly lowered plasma cholesterol level, reduced
endothelial damage and the severity of atherosclerosis in
diet-induced hypercholesteremic rabbits. The cardiovas-
cular protection potential of Sal B was contributed by
its ROS scavenging ability. Sal B-treated LDL exhibited
vitamin E-binding ability and was resistant to Cu2
+-induced oxidation [23]. Moreover, intravenous admin-
istration of Sal A (0.3-3 mg/kg) significantly attenuated
isoproterenol-induced cardiac dysfunction and myocar-
dial injury, and improved mitochondrial respiratory
function in rat with isoproterenol-induced myocardial
infarction [24].
It is known that increase in oxidative stress induced
the proliferation of aortic smooth muscle cells. Recently,
salvianolic acids were found to inhibit the proliferation
of rat aortic smooth muscle A10 cells stimulated by
homocysteine, an oxidative stress factor. Elucidation of
proteomic changes by two-dimensional electrophoresis
coupled with MALDI-TOF mass spectrometry revealed
that the inhibitory effect of the salvianolic acid on






Figure 1 Chemical structure of salvianolic acid A (Sal A) and Sal B. More than eighteen components can be identified in Radix S.
miltiorrhiza. Sal B is the most abundant while Sal A is the most potent water-soluble phenolic component in Radix S. miltiorrhiza.
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homocysteine-induced A10 cell proliferation was via the
PKC/p44/42 MAPK dependent pathway [25]. Interest-
ingly, salvianolic acid treatment reduces the carbonyla-
tion of specific cytoskeleton and chaperone proteins
such as vimentin, a4-tropomyosin and GRP75, and lead
to phenotype transformations in the rat A10 cells [25].
Apart from what have been mentioned above, salvia-
nolic acids have been reported to protect cardiomyo-
cytes from drug-induced toxicity due to its ROS
scavenging ability. It was noted that Sal A converted
HO· generated by electron transfer from adriamycin
semiquinone radicals to H2O2 on adriamycin-induced
mitochondrial toxicity of rat heart in a dose-dependent
manner [26]. In mice with doxorubicin-induced cardio-
toxicity, salvianolic acids (containing 64.92% Sal B, 40
mg/kg/day for 3 days) also protected myocardium
through reducing oxidative stress [27].
B.
Salvianolic Acids Inhibit Leukocyte-Endothelial Cell
Adherence
Leukocyte attachment, migration as well as adhesion
molecule expression on arterial endothelial cells all are
important steps in the development of early athero-
sclerosis. A series of studies on salvianolic acids regulat-
ing leukocyte-endothelial cell adherence have been
undertaken. It is well-established that endothelial-leuko-
cyte adhesion molecules on aortic endothelial cells can
be induced by TNF-a. Sal B was found to attenuate
VCAM-1 and ICAM-1, but not E-selectin expression, in
a dose-dependent manner (1-20 μg/ml), in TNF-a-treated
HAECs. These effects were associated with its anti-inflam-
matory property through inhibiting the activation of NFkB
pathway triggered by TNF-a [28].
Using Evans Blue dye-labeled bovine serum albumin
to investigate the alteration of permeability in HUVECs
caused by Sal B (20-50 μg/ml), it was found that Sal B
reduced the permeability and attenuated the disorgani-
zation of VE-cadherin induced by TNF-a in these cells.
The effect was attributed to the reduction of VEGF pro-
tein expression as a result of modulation of the ERK
pathway [29]. Loss of cell-cell adhesion junctions also
increased endothelial permeability. Dang et al demon-
strated the protective effect of Sal B on TNF-a-mediated
disorganization of endothelial cell junctions through
attenuating tyrosine phosphorylation of cell junction
proteins such as VE-cadherin and b-catenin. Results of
immuno-precipitation studies indicated that Sal B pre-
vented b-catenin disassociation from the cytoskeleton in
TNF-a-treated HUVECs [30].
Zhou et al reported that treatment with Sal B (0.05
and 0.15 μM) significantly inhibited PAI-1 gene expres-
sion in the first 18 hours when HUVECs were exposed
to TNF-a. It was further demonstrated that NFkB and
ERK-AP-1 pathways were possible targets of Sal B in
regulating TNF-a-stimulated PAI-1 production in
HUVECs [31].
C.
Salvianolic Acids Inhibit Inflammation And Regulation of
Metalloproteinaseses Expression During Cardiovascular
Injury
Synthesis and release of inflammatory cytokines from
vascular smooth muscle cells is an important contribu-
tor to the pathogenesis of atherosclerosis. Chen et al
and Lin et al reported respectively that genetic expres-
sion of COX-2 and protein expression of MMP-2 and
MMP-9 in LPS-treated HASMCs could be inhibited by
Sal B via the suppression of ERK1/2 and JNK phosphor-
ylation, reduction of PGE2 production and NADPH
oxidase activity [32,33]. In ApoE-deficient mice fed with
high cholesterol diet, supplementation with 0.3% of Sal
B protected mice from atherosclerosis by reducing the
thickness of intima, which was accompanied by a signifi-
cant reduction of COX-2, MMP-2 and MMP-9 expres-
sion [32,33].
Sal B not only inhibited MMP-2 activation induced by
LPS, but also inhibited MMP-2 activation induced by
TNF-a, angiotension II and H2O2. It has been demon-
strated that Sal B inhibited TNF-a, angiotension II and
H2O2-induced MMP-2 mRNA, protein expression, and
gelatinolytic activity in HASMCs in a concentration-
dependent manner (0.1-10 μM), which was through the
inhibition of NADPH oxidase-dependent ROS genera-
tion [34].
In experimental myocardial infarction in rat, Jiang et
al reported that administration of salvianolic acids sig-
nificantly decreased infarct size, improved left ventricu-
lar function and decreased myocardial malondialdehyde
levels compared with the control group. The cardiopro-
tection of salvianolic acids against infarct-induced left
ventricle remodeling was significantly contributed by the
down-regulation of MMP-9 mRNA expression level and
its activity at the infarct area [35]. With molecular mod-
eling, in-gel gelatin zymography and enzymatic analysis,
Jiang et al demonstrated that Sal B (from 0-70 μM)
bound to MMP-9 at catalytic domain and functioned as
a competitive inhibitor of MMP-9 [36].
D.
Salvianolic Acids Regulate Kinase Activity and are
Potential Immunomodulators
Recently, the putative protein targets of salvianolic acids
have been investigated [37]. In addition to MMP-9 binding
affinity [36], salvianolic acids regulate intracellular kinase-
associated signaling pathway [28,29,31-34], indicating that
salvianolic acids interact with phosphotyrosine or phospho-
serine/threonine-binding domain [38,39]. With binding
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affinity assay and molecular modeling prediction, Sperl et
al reported that Sal A and Sal B were inhibitors of the pro-
tein-protein interaction mediated by SH2 domains of Src-
family kinases Src and Lck. The potency of Sal A and Sal B
(from 0-100 μM) binding to Src and Lck were higher than
rosmarinic acid, a nature product known as a Lck SH2
domain inhibitor [40]. Since Lck is a T cell-restricted Src
family protein tyrosine kinase and is crucial in TCR-
mediated signaling pathway, the activity of rosmarinic acid
against Lck SH2 domain has been used experimentally as
an immune-suppressive agent [41] and becomes a focus of
cancer drug discovery [42].
Recently, Wang et al reported that using an ELISA-
like HTS assay, Sal B and rosmarinic acid were found to
be active compounds showing high affinity against
CD36, a high affinity receptor for oxLDL, thus pre-
vented oxLDL from macrophage uptake [43]. Since both
Sal A and Sal B shared the core structure of rosmarinic
acid [40], the high affinity to SH2 domains of Src-family
kinases and CD36 suggested the role of immune modu-
lator in the cardiovascular protective effect of salvianolic
acids.
Conclusion
Salvianolic acids, which contain polyphenolic structure,
are potent antioxidants. Salvianolic acids reduce intra-
cellular as well as intravascular oxidative stress, which
protects endothelial cells, arterial smooth muscle cells,
cardiomyocyte, and LDL form free radical damage and
peroxidation. In addition, salvianolic acids attenuate
endothelial-leukocyte adhesion molecules expression on
vascular endothelial cells through regulating intracellular
kinase activity. Such kinase-associated signaling pathway
inhibition by salvianolic acids also contributes their anti-
inflammation effect. Salvianolic acids possess strong affi-
nity to bind MMP-9, SH2 domain of the Src-family
kinases and CD36, which inhibits protein-protein inter-
action. For clinical application, intravenous injection
rather than oral administration of such a water-soluble
compound is more easily to reach the therapeutic
plasma concentration. Taken together, the cardiovascu-
lar protective effect of salvianolic acids is mediated
through multiple molecular mechanisms. Such unique
property makes salvianolic acids excellent candidates for
future development of cardiovascular protective agents.
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